The ability of AT101, in a single injection, to target the GPC1 protein on the cell surface and activate the immune response at the tumor prompted us to investigate its efficacy as an antibody-based immunotherapeutic in the PDAC xenograft mouse model. This evidence concerns the gene GPC1 and neoplasm.